I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
COVID-19-Led Disruptions Exhaust Radiopharmaceuticals Supply to
Hinder Nuclear Medicine Procedures in Most Countries
Imaging Screening Volume % Change 1H 2019 Vs 1H 2020 in U.S
Hospitals
Distribution Bottlenecks amid COVID-19 Crisis Leave Hospitals
Struggling with Seamless Supply of Medical Radioisotopes
Nuclear Medicine Services Limp Back to Normality after Easing
of COVID-19 Restrictions
COVID-19 Presents Generational Opportunity
Radiopharmaceuticals: A Prelude
Mechanism of Action
Global Supply Shortages Continue to Challenge Market Growth
EXHIBIT 1: A Glimpse at Mo-99 Processors Worldwide
EXHIBIT 2: Nuclear Research Reactor Irradiators Worldwide:
A Snapshot
Outlook
Key Market Drivers
Market Restraints
Recognition of Intrinsic Cost Benefits: Critical to Market
Acceptance
Classification of Radiopharmaceuticals
Diagnostic Radiopharmaceuticals: The Dominant Segment
Key Drivers
Positron Emission Tomography (PET)
Major PET Isotopes and their Applications
Single Photon Emission Computed Tomography (SPECT)
Major Isotopes and their Diagnostic Applications
Therapeutic Radiopharmaceuticals
Select Isotopes and their Therapeutic Applications
Key Drivers
Competitive Landscape
EXHIBIT 3: Radiopharmaceuticals Competitor Market Share
Scenario Worldwide (in %): 2019
Recent Industry Activity
World Brands

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Emergence of Radiotheranostics: Dual-Functioning
Radiopharmaceuticals
Changing Role of Radiopharmaceuticals in Diagnostic and
Therapeutic Applications
Advent of New Radiopharmaceuticals Widen Scope
Select New Products
Industry Focus Gears up for Innovative Radiopharmaceuticals
with Therapeutic Benefits
Select Commercially Available Therapeutic Radiopharmaceuticals
PET Eclipses SPECT in Cardiovascular Imaging
EXHIBIT 4: Worldwide Installed Base of Nuclear Imaging
Equipment by Modality, PET Vs SPECT: 2019
Cardiac Amyloidosis Visualization: A Potential Application for PET
Innovative Radiopharmaceuticals to Boost Cardiac Applications
EXHIBIT 5: Fatalities by Heart Conditions - Estimated
Percentage Breakdown for Cardiovascular Disease, Ischemic
Heart Disease, Stroke, and Others
Application of PET in Drug Development to Expand Opportunities
Intra-operative Lymphatic Mapping (ILM): Creates New
Opportunities for Radiopharmaceuticals in Cancer Detection
Personalized Medicine Drives Nuclear Medicine
XHIBIT: Drug Ineffectiveness for Select Therapeutic Categories
as a Percentage of Patient Population
EXHIBIT 6: Global Personalized Medicine Market: Revenues in US$
Million for the Years 2019 and 2024
Rise in Incidence of Neurological Disorders to Drive Growth
Rising Cancer Incidence Worldwide Spurs Demand
EXHIBIT 7: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 8: Global Number of New Cancer Cases and Cancer-related
Deaths by Cancer Site for 2018
EXHIBIT 9: Number of New Cancer Cases and Deaths (in Million)
by Region for 2018
Ageing Population: A Vital Demography
EXHIBIT 10: Global Aging Population: Population of 65+
Individuals (in Thousands) by Region for 2019 and 2030
EXHIBIT 11: Global Cancer Deaths by Age Group (in %) for 2019
Rise in Healthcare Expenditure to Drive Growth
EXHIBIT 12: Elderly Healthcare Expenditure as a % of GDP
EXHIBIT 11: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023
Relevant Aspects of Radiopharmaceutical Production
Regulatory Regime Governing Production and Use of
Radiopharmaceuticals

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for
Radiopharmaceuticals by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Radiopharmaceuticals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 3: World 11-Year Perspective for Radiopharmaceuticals by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2016, 2020 & 2027

Table 4: World Current & Future Analysis for SPECT
Radioisotopes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for SPECT Radioisotopes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 6: World 11-Year Perspective for SPECT Radioisotopes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027

Table 7: World Current & Future Analysis for PET Radioisotopes
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for PET Radioisotopes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 9: World 11-Year Perspective for PET Radioisotopes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027

Table 10: World Current & Future Analysis for Beta Emitters by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Beta Emitters by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019 and
% CAGR

Table 12: World 11-Year Perspective for Beta Emitters by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027

Table 13: World Current & Future Analysis for Alpha Emitters by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Alpha Emitters by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 15: World 11-Year Perspective for Alpha Emitters by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027

Table 16: World Current & Future Analysis for Other Product
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Other Product Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 18: World 11-Year Perspective for Other Product Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027

Table 19: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019 and
% CAGR

Table 21: World 11-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2016, 2020 & 2027

Table 22: World Current & Future Analysis for Cardiology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Cardiology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019 and
% CAGR

Table 24: World 11-Year Perspective for Cardiology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027

Table 25: World Current & Future Analysis for Neurology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Neurology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2016 through 2019 and
% CAGR

Table 27: World 11-Year Perspective for Neurology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2016, 2020 & 2027

Table 28: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 30: World 11-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027

Table 31: World Current & Future Analysis for Hospitals &
Diagnostic Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Hospitals & Diagnostic
Centers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2016 through 2019 and % CAGR

Table 33: World 11-Year Perspective for Hospitals & Diagnostic
Centers by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2016, 2020 &
2027

Table 34: World Current & Future Analysis for Ambulatory
Surgical Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Ambulatory Surgical Centers
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 36: World 11-Year Perspective for Ambulatory Surgical
Centers by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2016, 2020 &
2027

Table 37: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 38: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 39: World 11-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Market Overview
Diagnostic Applications Stimulate Future Growth
Demographic Changes Offer Growth Opportunities
EXHIBIT 13: US Elderly Population: Expected Growth Rates Over
the Years 2005-2025
Rising Incidence of Cancer: A Major Growth Driver
EXHIBIT 14: Leading Sites of New Cancer Cases in Males: 2020
EXHIBIT 15: Leading Sites of New Cancer Cases in Females: 2020
Cardiovascular Imaging to Lead Volume Growth
Radiopharmaceuticals Usage Strengthens in PET Imaging
Radioisotope/Radiopharmaceuticals Supply Scenario
Passing of Medicare Diagnostic Radiopharmaceutical Payment
Equity Act
Table 40: USA Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 42: USA 11-Year Perspective for Radiopharmaceuticals by
Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027

Table 43: USA Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 44: USA Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 45: USA 11-Year Perspective for Radiopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Cardiology, Neurology and Other Applications for the Years
2016, 2020 & 2027

Table 46: USA Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 47: USA Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 and %
CAGR

Table 48: USA 11-Year Perspective for Radiopharmaceuticals by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027

CANADA
Market Overview
Efforts on to Address Mo-99 Supply Shortage
Table 49: Canada Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 51: Canada 11-Year Perspective for Radiopharmaceuticals
by Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027

Table 52: Canada Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 53: Canada Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 54: Canada 11-Year Perspective for Radiopharmaceuticals
by Application - Percentage Breakdown of Value Sales for
Oncology, Cardiology, Neurology and Other Applications for the
Years 2016, 2020 & 2027

Table 55: Canada Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 56: Canada Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 and %
CAGR

Table 57: Canada 11-Year Perspective for Radiopharmaceuticals
by End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027

JAPAN
Market Overview
Table 58: Japan Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 60: Japan 11-Year Perspective for Radiopharmaceuticals by
Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027

Table 61: Japan Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 62: Japan Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 63: Japan 11-Year Perspective for Radiopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Cardiology, Neurology and Other Applications for the Years
2016, 2020 & 2027

Table 64: Japan Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 and %
CAGR

Table 66: Japan 11-Year Perspective for Radiopharmaceuticals by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027

CHINA
Market Overview
Table 67: China Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 69: China 11-Year Perspective for Radiopharmaceuticals by
Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027

Table 70: China Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 71: China Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 72: China 11-Year Perspective for Radiopharmaceuticals by
Application - Percentage Breakdown of Value Sales for Oncology,
Cardiology, Neurology and Other Applications for the Years
2016, 2020 & 2027

Table 73: China Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 74: China Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 and %
CAGR

Table 75: China 11-Year Perspective for Radiopharmaceuticals by
End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027

EUROPE
Market Overview
Table 76: Europe Current & Future Analysis for
Radiopharmaceuticals by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Radiopharmaceuticals by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2016 through 2019 and % CAGR

Table 78: Europe 11-Year Perspective for Radiopharmaceuticals
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2016, 2020 & 2027

Table 79: Europe Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 81: Europe 11-Year Perspective for Radiopharmaceuticals
by Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027

Table 82: Europe Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 83: Europe Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 84: Europe 11-Year Perspective for Radiopharmaceuticals
by Application - Percentage Breakdown of Value Sales for
Oncology, Cardiology, Neurology and Other Applications for the
Years 2016, 2020 & 2027

Table 85: Europe Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 86: Europe Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 and %
CAGR

Table 87: Europe 11-Year Perspective for Radiopharmaceuticals
by End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027

FRANCE
Table 88: France Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Radiopharmaceuticals by
Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta
Emitters, Alpha Emitters and Other Product Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2016 through 2019 and % CAGR

Table 90: France 11-Year Perspective for Radiopharmaceuticals
by Product Type - Percentage Breakdown of Value Sales for SPECT
Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters
and Other Product Types for the Years 2016, 2020 & 2027

Table 91: France Current & Future Analysis for
Radiopharmaceuticals by Application - Oncology, Cardiology,
Neurology and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 92: France Historic Review for Radiopharmaceuticals by
Application - Oncology, Cardiology, Neurology and Other
Applications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 93: France 11-Year Perspective for Radiopharmaceuticals
by Application - Percentage Breakdown of Value Sales for
Oncology, Cardiology, Neurology and Other Applications for the
Years 2016, 2020 & 2027

Table 94: France Current & Future Analysis for
Radiopharmaceuticals by End-Use - Hospitals & Diagnostic
Centers, Ambulatory Surgical Centers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 95: France Historic Review for Radiopharmaceuticals by
End-Use - Hospitals & Diagnostic Centers, Ambulatory Surgical
Centers and Other End-Uses Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2016 through 2019 and %
CAGR

Table 96: France 11-Year Perspective for Radiopharmaceuticals
by End-Use - Percentage Breakdown of Value Sales for Hospitals &
Diagnostic Centers, Ambulatory Surgical Centers and Other
End-Uses for the Years 2016, 2020 & 2027

GERMANY
Table 97: Germany Current & Future Analysis for
Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET
Radioisotopes, Beta Emitters, Alpha Emitters and Other Product
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 t